Bioasis Technologies' xB3 Platform Unlocks Revolutionary Neurological Disease Treatments

NEW HAVEN, Conn. – Feb 18, 2022 – BIOASIS TECHNOLOGIES INC. BTI BIOAF, (the “Company” or “Bioasis”), is a biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. 

The blood-brain barrier is a major hurdle in treating a whole range of diseases affecting the CNS. While it serves a vital role in protecting against blood-borne pathogens, it also prevents the delivery of many pharmaceutical drugs. Now, an innovation from

Bioasis Technologies Inc. is set to overcome this obstacle, unlocking new treatment vectors for brain cancer and neurodegenerative diseases. 

According to Dr. Mei Mei Tian, vice president and the head of external research at Bioasis Technologies, Inc.: 

“Treatment of diseases and disorders affecting the central nervous system is a significant area of unmet need in global health. One of the critical factors affecting the success of development programs targeting treatments for CNS disorders is the challenges with delivery of drugs into the brain across the blood-brain barrier. 

Bioasis’ proprietary xB3 platform technology acts as a brain delivery vector, transforming either existing or novel non-brain penetrating therapeutics into new, more efficacious agents that are able to also cross the blood-brain barrier to engage targets in the brain. 

We have demonstrated success in various preclinical disease models in the areas of brain cancer and neurodegenerative diseases, both through internal R&D and external validating partnerships. 

At Bioasis, we are actively and continuously developing our xB3 platform technology to overcome the challenges of drug brain delivery, especially in the area of rare diseases.” 

About Bioasis Technologies Inc.:

Bioasis Technologies Inc. BTIBIOAF is a biopharmaceutical company developing the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases.